The growing buzz around GLP-1 drugs like Ozempic is shifting away from just weight loss and focusing more on their potential to treat a wide range of other health conditions — a development that could lead to complications for both patients and insurers. These medications, originally developed for diabetes, are now being linked to reduced risks of Alzheimer’s disease, addiction, sleep apnea, seizures, and bacterial infections, with more possible applications being discovered over time. This has led many to view them as potential “wonder drugs.” However, despite the excitement, there is still a great deal we don’t fully understand about how they work. It remains uncertain whether the benefits of GLP-1 drugs are due to their direct effects or if they simply address problems that stem from obesity and diabetes, which are known to contribute to numerous other health issues. As research continues and demand grows, both the medical community and the insurance industry will have to grapple with how to approach these drugs responsibly and effectively. Read More